WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205742
Description: NKP-2235, also known as IT-235, is a first-in-class orally available gallium-based anticaner small molecule that targets the endoplasmic reticulum with a unique pattern of cytotoxicity. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly. NKP-2235 were discovered by Professor Bernhard Keppler, University of Vienna, Austria.
MedKoo Cat#: 205742
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NKP2235; NKP 2235; NKP-2235; IT-235; IT235; IT 235.
IUPAC/Chemical Name: NONE
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
NKP-2235 is a first-in-class targeted gallium-based small molecule. It is orally bioavailable and given as a tablet. NKP-2235, is currently being developed by Niiki Pharma. According to its website, NKP-2235 targets the endoplasmic reticulum. Unlike normal cells, tumor cells are known to be under high levels of stress due to factors such as hypoxia, acidosis and glucose deprivation. This leads to high levels of protein misfolding and other stress effects. Endoplasmic reticulum is the cell machinery that repairs protein misfolding. In tumor cells, the endoplasmic reticulum in is under stress due to the high levels of misfolded proteins and other factors. NKP-2235 induces additional endoplasmic reticulum stress, leading to an overload of the system, which triggers tumor cell death.